X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs DISHMAN PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA DISHMAN PHARMA CIPLA/
DISHMAN PHARMA
 
P/E (TTM) x 43.5 25.1 173.4% View Chart
P/BV x 3.6 3.3 107.2% View Chart
Dividend Yield % 0.4 0.7 53.9%  

Financials

 CIPLA   DISHMAN PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
DISHMAN PHARMA
Mar-16
CIPLA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs622374 166.1%   
Low Rs458129 355.5%   
Sales per share (Unadj.) Rs181.9197.8 91.9%  
Earnings per share (Unadj.) Rs12.921.2 60.7%  
Cash flow per share (Unadj.) Rs29.334.7 84.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.40.8 46.6%  
Book value per share (Unadj.) Rs155.7179.9 86.5%  
Shares outstanding (eoy) m804.5180.69 997.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.3 233.4%   
Avg P/E ratio x42.011.9 353.6%  
P/CF ratio (eoy) x18.47.2 254.2%  
Price / Book Value ratio x3.51.4 248.0%  
Dividend payout %15.59.4 164.8%   
Avg Mkt Cap Rs m434,51620,306 2,139.9%   
No. of employees `00023.00.8 2,779.6%   
Total wages/salary Rs m26,3385,355 491.9%   
Avg. sales/employee Rs Th6,349.119,252.7 33.0%   
Avg. wages/employee Rs Th1,143.06,459.5 17.7%   
Avg. net profit/employee Rs Th449.32,064.1 21.8%   
INCOME DATA
Net Sales Rs m146,30215,961 916.7%  
Other income Rs m2,287265 861.7%   
Total revenues Rs m148,58916,226 915.8%   
Gross profit Rs m24,7584,103 603.4%  
Depreciation Rs m13,2291,091 1,213.0%   
Interest Rs m1,594944 168.8%   
Profit before tax Rs m12,2222,334 523.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-701 -6,354.5%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798624 288.3%   
Profit after tax Rs m10,3541,711 605.1%  
Gross profit margin %16.925.7 65.8%  
Effective tax rate %14.726.7 55.0%   
Net profit margin %7.110.7 66.0%  
BALANCE SHEET DATA
Current assets Rs m87,37011,018 793.0%   
Current liabilities Rs m33,0819,517 347.6%   
Net working cap to sales %37.19.4 394.6%  
Current ratio x2.61.2 228.1%  
Inventory Days Days87110 78.7%  
Debtors Days Days6235 178.9%  
Net fixed assets Rs m111,56716,304 684.3%   
Share capital Rs m1,609161 996.9%   
"Free" reserves Rs m123,64512,907 958.0%   
Net worth Rs m125,25414,516 862.9%   
Long term debt Rs m36,4544,189 870.1%   
Total assets Rs m209,53229,805 703.0%  
Interest coverage x8.73.5 249.7%   
Debt to equity ratio x0.30.3 100.8%  
Sales to assets ratio x0.70.5 130.4%   
Return on assets %5.78.9 64.0%  
Return on equity %8.311.8 70.1%  
Return on capital %8.517.5 48.5%  
Exports to sales %34.224.8 138.0%   
Imports to sales %8.33.7 223.2%   
Exports (fob) Rs m50,0503,956 1,265.1%   
Imports (cif) Rs m12,203596 2,046.4%   
Fx inflow Rs m51,0664,952 1,031.3%   
Fx outflow Rs m17,678697 2,537.0%   
Net fx Rs m33,3884,255 784.7%   
CASH FLOW
From Operations Rs m23,8242,786 855.0%  
From Investments Rs m-13,127-1,529 858.6%  
From Financial Activity Rs m-13,239-941 1,406.7%  
Net Cashflow Rs m-2,478316 -783.2%  

Share Holding

Indian Promoters % 16.0 61.4 26.1%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 3.7 329.7%  
FIIs % 23.7 12.7 186.6%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 22.1 118.6%  
Shareholders   161,166 46,261 348.4%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   FRESENIUS KABI ONCO.  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; Auto Stocks Witness Selling(01:30 pm)

After opening the day flat, share markets in India continued to witness selling pressure and are currently trading in red. Sectoral indices are trading on a mixed note with stocks in the metals sector.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Aug 21, 2017 01:59 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS